Rituximab-based immunosuppression for autoimmune haemolytic anaemia in infants

被引：16

作者：

Svahn, Johanna ^{[1
]}

Fioredda, Francesca ^{[1
]}

Calvillo, Michaela ^{[1
]}

Molinari, Angelo C. ^{[1
]}

Micalizzi, Concetta ^{[1
]}

Banov, Laura ^{[1
]}

Schmidt, Madalina ^{[1
,2
]}

Caprino, Daniela ^{[1
]}

Marinelli, Doretta ^{[3
]}

Gallisai, Domenico ^{[4
]}

Dufour, Carlo ^{[1
]}

机构：

[1] G Gaslini Childrens Inst, Haematol Unit, I-16148 Genoa, Italy

[2] Santa Maria Childrens Hosp, Iasi, Romania

[3] Perugia Hosp, Neonatal Intens Care Unit, Perugia, Italy

[4] Univ Sassari, Dept Paediat, I-07100 Sassari, Italy

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2009年 / 145卷 / 01期

关键词：

autoimmune haemolytic anaemia; infants; rituximab; cyclosporine A; IMMUNODEFICIENCY;

D O I：

10.1111/j.1365-2141.2009.07594.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We report a case series of four infants with severe autoimmune haemolytic anaemia (AIHA) who responded to treatment with rituximab and cyclosporine after having failed first line therapy with high-dose steroid (prednisolone 4-8 mg/kg/d). Rituximab was started at 11-90 d from onset due to continued haemolysis; three infants also received cyclosporine A. Three of four infants reached complete response, defined as normal haemoglobin, reticulocytes and negative indices of haemolysis, at 7-21 months from diagnosis. In long-term follow-up two infants remained disease-free with normal immunology, one had undefined immunodeficiency and one had autoimmune lymphoproliferative syndrome.

引用

页码：96 / 100

页数：5

共 15 条

[1] Molecular basis of common variable immunodeficiency [J].

Castigli, E ;

Geha, RS .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (04) :740-746

[2]

*FDA CTR DRUG EV R, 2006, FDA PUBL HLTH ADV LI

[3] Treatment with rituximab in benign and malignant hematologic disorders in children [J].

Giulino, Lisa B. ;

Bussel, James B. ;

Neufeld, Ellis J. .

JOURNAL OF PEDIATRICS, 2007, 150 (04) :338-344

[4] Successful induction and maintenance of long-term remission in a child with chronic relapsing autoimmune hemolytic anemia using rituximab [J].

Gottardo, NG ;

Baker, DL ;

Willis, FR .

PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2003, 20 (07) :557-561

[5] Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development [J].

Klink, D. T. ;

van Elburg, R. M. ;

Schreurs, M. W. J. ;

van Well, G. T. J. .

CLINICAL & DEVELOPMENTAL IMMUNOLOGY, 2008,

[6]

LARRAR S, 2006, HAEMATOL S, V8, pECR36

[7]

MOTTA M, 2003, FETAL NEONATAL EDITI, V88, pF341

[8]

NATHAN DG, 2003, APPENDIX 27 NATHAN O

[9] Anti B cell targeted immunotherapy for treatment of refractory autoimmune haemolytic anaemia in a young infant [J].

Ng, PC ;

Lee, KKM ;

Lo, AFC ;

Li, CK ;

Fok, TF .

ARCHIVES OF DISEASE IN CHILDHOOD, 2003, 88 (04) :337-339

[10] Fatal warm autoimmune hemolytic anemia resulting from IgM autoagglutinins in an infant with severe combined immunodeficiency [J].

Nowak-Wegrzyn, A ;

King, KE ;

Shirey, RS ;

Chen, AR ;

McDonough, C ;

Lederman, HM .

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2001, 23 (04) :250-252

← 1 2 →